Misplaced Pages

Samatasvir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Samatasvir
Clinical data
Routes of
administration		Oral
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • N-((1R)-2-((2S)-2-(5-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-3H-benzimidazol-5-yl)thieno(3,2-b)thiophen-3-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC47H48N8O6S2
Molar mass885.07 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C(=O)N1CCC1c2c3ccc(cc3n2)c4csc5c4scc5c6ccc(cc6)c7cc(n7)8CCCN8C(=O)(c9ccccc9)NC(=O)OC)NC(=O)OC
InChI
  • InChI=1S/C47H48N8O6S2/c1-26(2)38(52-46(58)60-3)44(56)55-21-9-13-37(55)43-49-33-19-18-30(22-34(33)50-43)32-25-63-40-31(24-62-41(32)40)27-14-16-28(17-15-27)35-23-48-42(51-35)36-12-8-20-54(36)45(57)39(53-47(59)61-4)29-10-6-5-7-11-29/h5-7,10-11,14-19,22-26,36-39H,8-9,12-13,20-21H2,1-4H3,(H,48,51)(H,49,50)(H,52,58)(H,53,59)/t36-,37-,38-,39+/m0/s1
  • Key:ATOLIHZIXHZSBA-BTSKBWHGSA-N

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.

Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex. While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.

See also

References

  1. Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, et al. (May 2014). "A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4". Journal of Hepatology. 60 (5): 920–7. doi:10.1016/j.jhep.2014.01.003. PMID 24434503.
  2. Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, et al. (August 2014). "In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus". Antimicrobial Agents and Chemotherapy. 58 (8): 4431–42. doi:10.1128/AAC.02777-13. PMC 4136001. PMID 24867983.
  3. Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: